As of 2026-04-22, the Intrinsic Value of Anavex Life Sciences Corp (AVXL) is -2.16 USD. This Anavex valuation is based on the model Peter Lynch Fair Value. With the current market price of 3.61 USD, the upside of Anavex Life Sciences Corp is -159.70%.
Based on its market price of 3.61 USD and our intrinsic valuation, Anavex Life Sciences Corp (AVXL) is overvalued by 159.70%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -2.16 - -2.16 | -2.16 | -159.70% |
| P/E | (7.71) - (9.19) | (8.45) | -334.0% |
| DDM - Stable | (2.93) - (13.44) | (8.19) | -326.8% |
| DDM - Multi | (0.80) - (3.02) | (1.28) | -135.5% |
| Market Cap (mil) | 334.54 |
| Beta | 1.68 |
| Outstanding shares (mil) | 92.67 |
| Enterprise Value (mil) | 202.79 |
| Market risk premium | 4.60% |
| Cost of Equity | 10.59% |
| Cost of Debt | 5.00% |
| WACC | 7.79% |